Dr. Thomas Gajewski on Analyzing the Tumor Microenvironment to Guide Immunotherapy in Melanoma

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.

Cancer Network spoke with Thomas Gajewski, MD, PhD, of the University of Chicago Medical Center, about analyzing the tumor microenvironment to guide immunotherapy in melanoma.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Related Content
The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Novel Cancer Vaccine Combos Show Efficacy, Safety in Late-Stage Melanoma

Tim Cortese
July 22nd 2025
Article

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

The B7-H3-low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.

Nivolumab Plus Relatlimab Shows Long-Term EFS Benefit in Advanced Melanoma

Tim Cortese
July 14th 2025
Article

The B7-H3–low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD, PhD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

In those being screened for hereditary breast and ovarian cancer syndrome, use of a video tool improved the duration of physician-led genetic counseling.

Video-Based Genetic Counseling Improves Comprehension in HBOC

Tim Cortese
July 3rd 2025
Article

In those being screened for hereditary breast and ovarian cancer syndrome, use of a video tool improved the duration of physician-led genetic counseling.

Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

Tim Cortese
June 20th 2025
Article

Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.